Souhaitez-vous accéder aux communiqués récents ?

AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Prog

Cathie Wood and ARK Invest are making a decisive pivot that signals where the next phase of AI value creation may emerge: healthcare

Marvel Biosciences secures $600,000 in non-dilutive funding from Alberta Innovates to support Phase I clinical trials of its autism-focused patented MB-204

Thera Liechtenstein brings extensive biotech investment and company‑building experience to new role as Partner at 4BIO CapitalTetsu Maruyama, former Head of Drug Discovery at Takeda Pharmaceuticals,...

Envudeucitinib late-breaking data at AAD: early and robust improvements in skin clearance, quality of life and psoriasis symptoms in two Phase 3 trials

Neion Bio exits stealth with first biosimilar co-development and supply partnership, leveraging its genetic engineering platform to enable scalable, lower-

Eascra Biotech, a nanomedicine startup, has won first place at the TechConnect Bio in Space Innovation Challenge

BEIJING, March 25, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the annual...

Marvel Biosciences Selects Novotech as CRO for Its Phase I Clinical Trial of MB-204, lead asset discovery, a patented neuroactive adenosine A2A antagonist

Cellbricks raises €10M to advance biofabricated tissue implants for soft tissue repair, moving toward clinical validation and future organ replacement.